Mimedx (MDXG) Asset Writedowns and Impairment (2016 - 2026)
Mimedx recorded quarterly Asset Writedowns and Impairment of $1.5 million in Q1 2026, down 56.51% quarter-over-quarter from $3.4 million in Q4 2025, and up 97.3% year-over-year from $742000.0 in Q1 2025.
Mimedx's Asset Writedowns and Impairment history runs 10 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment rose 97.3% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $7.2 million (up 536.5% YoY), while the FY2025 annual figure was $6.5 million, up 994.96% from the prior year.
- Asset Writedowns and Impairment came in at $1.5 million for Q1 2026 at Mimedx, down from $3.4 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $3.4 million in Q4 2025 to a low of -$279000.0 in Q3 2024.
- A 5-year average of $834687.5 and a median of $436500.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Across the five-year window, Asset Writedowns and Impairment jumped 48200.0% in 2023 and slumped 162.42% in 2024, its largest moves.
- Mimedx's Asset Writedowns and Impairment stood at $3000.0 in 2022, then surged by 48200.0% to $1.4 million in 2023, then plunged by 68.67% to $454000.0 in 2024, then surged by 641.41% to $3.4 million in 2025, then slumped by 56.51% to $1.5 million in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $1.5 million, $3.4 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.46 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 3.37 Mn |
| Dec 31, 2025 | 3.37 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 351,000.00 |
| Jun 30, 2025 | 351,000.00 |
| Mar 31, 2025 | 742,000.00 |
| Mar 31, 2025 | 742,000.00 |
| Dec 31, 2024 | 454,000.00 |
| Dec 31, 2024 | 454,000.00 |
| Sep 30, 2024 | -279,000.00 |
| Sep 30, 2024 | -279,000.00 |
| Jun 30, 2024 | 220,000.00 |
| Jun 30, 2024 | 220,000.00 |
| Mar 31, 2024 | 199,000.00 |
| Mar 31, 2024 | 199,000.00 |
| Dec 31, 2023 | 1.45 Mn |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 447,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Jun 30, 2023 | 349,000.00 |
| Jun 30, 2023 | 349,000.00 |
| Mar 31, 2023 | -60,000.00 |
| Mar 31, 2023 | -60,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 426,000.00 |
| Sep 30, 2022 | 426,000.00 |
| Jun 30, 2022 | 2.17 Mn |
| Jun 30, 2022 | 2.17 Mn |
| Dec 31, 2021 | 53,000.00 |
| Dec 31, 2021 | 53,000.00 |
| Dec 31, 2020 | 1.17 Mn |
| Dec 31, 2020 | 1.17 Mn |
| Sep 30, 2020 | -171,000.00 |
| Sep 30, 2020 | -171,000.00 |
| Dec 31, 2019 | 845,000.00 |
| Dec 31, 2019 | 845,000.00 |
| Sep 30, 2019 | -845,000.00 |
| Sep 30, 2019 | -845,000.00 |
| Mar 31, 2019 | 1.26 Mn |
| Mar 31, 2019 | 1.26 Mn |
| Dec 31, 2017 | 387,000.00 |
| Dec 31, 2017 | 387,000.00 |
| Sep 30, 2017 | 50,000.00 |
| Sep 30, 2017 | 50,000.00 |
| Jun 30, 2017 | 78,000.00 |
| Jun 30, 2017 | 78,000.00 |
| Mar 31, 2017 | 75,000.00 |
| Mar 31, 2017 | 75,000.00 |
| Dec 31, 2016 | 14,000.00 |
| Dec 31, 2016 | 14,000.00 |
| Sep 30, 2016 | 247,000.00 |
| Sep 30, 2016 | 247,000.00 |
| Jun 30, 2016 | 490,000.00 |
| Jun 30, 2016 | 490,000.00 |
| Mar 31, 2016 | 734,000.00 |
| Mar 31, 2016 | 734,000.00 |